Martin Turner
Head of Immunology Programme, Associate Director at Babraham Institute
After graduating in Biochemistry from UCL Martin Turner completed a PhD with Marc Feldmann studying the regulation of cytokine gene expression where he contributed to the basic science studies that led to the identification of TNF as a target in rheumatoid arthritis. He worked with Victor Tybulewicz at the MRC-NIMR where he identified elements of signal transduction necessary for the development of lymphocytes. He joined the Babraham Institute in 1997 where he continued research into signal transduction identifying roles for PI3K in lymphocyte development and activation. Some of this work underpinned the rationale for the use of inhiitors of PI3K delta in human malignancy. Recent work by his group seeks to understand how RNA-processing mechanisms control the development and function of B and T lymphocytes. He is interested in RNA-binding proteins and microRNAs and how these function within signal transduction networks to control cell differentiation and immunity.
Visit website: https://www.babraham.ac.uk/our-research/immunology/martin-turner
See alsoBabraham Institute
Life sciences research institution and a partner organisation of the University of Cambridge.
Details last updated 27-Jul-2025
Martin Turner is also referenced in the following:
74th Annual Scientific Meeting of the BSRA (2025)
03-Sep-2025
A compelling lineup of speakers from all areas of the biology of ageing (Manchester, UK)